Inhaled corticosteroids: Effects on the airway vasculature in bronchial asthma

European Respiratory Journal

Volumn 27, Issue 1, 2006, Pages 172-187

  Horvath, G ^a,b   Wanner, A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Airway vascularity; Angiogenesis; Asthma; Inhaled corticosteroids; Nongenomic action; Vasoconstriction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID RECEPTOR; HISTAMINE; MEMBRANE RECEPTOR; SALBUTAMOL; TERAZOSIN;

AEROSOL; AIRWAY CONDUCTANCE; AIRWAY CONSTRICTION; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLOOD FLOW VELOCITY; BLOOD VESSEL PERMEABILITY; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FUNCTIONAL GENOMICS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; HUMAN; HYPEREMIA; IN VIVO STUDY; INFLAMMATORY CELL; LUNG BLOOD FLOW; LUNG VASOCONSTRICTION; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TEST; SYMPTOMATOLOGY; TRANSACTIVATION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; UPREGULATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ASTHMA; BLOOD FLOW VELOCITY; BRONCHI; BRONCHOCONSTRICTION; GENOME; HUMANS; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; VASOCONSTRICTION; VASODILATION;

EID: 30744443041     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00048605     Document Type: Review

References (216)

1. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thor Soc 2004; 1: 176-183.
2. Charan NB, Baile EM, Pare PD. Bronchial vascular congestion and angiogenesis. Eur Respir J 1997; 10: 1173-1180.
3. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001; 164: S39-S45.
4. Mitzner W, Wagner EM. Vascular remodeling in the circulations of the lung. J Appl Physiol 2004; 97: 1999-2004.
5. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998; 158: 153-156.
6. Mendes ES, Campos MA, Hurtado A, Wanner A. Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma. Am J Respir Crit Care Med 2004; 169: 1131-1134.
7. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest 2002; 122: 166-170.
8. Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004; 169: 1125-1130.
9. Brown RH, Zerhouni EA, Mitzner W. Airway edema potentiates airway reactivity. J Appl Physiol 1995; 79: 1242-1248.
10. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997; 156: 229-233.
11. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999; 54: 289-295.
12. Vrugt B, Wilson S, Bron A, Holgate ST, Djukanovic R, Aalbers R. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J 2000; 15: 1014-1021.
13. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001; 56: 902-906.
14. Nocker RE, Weller FR, Out TA, de Riemer MJ, Jansen HM, van der Zee JS. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Am J Respir Crit Care Med 1999; 159: 1499-1505.
15. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001; 107: 1034-1038.
16. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001; 107: 295-301.
17. Chetta A, Zanini A, Foresi A, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003; 167: 751-757.
18. Otani K, Kanazawa H, Fujiwara H, Hirata K, Fujimoto S, Yoshikawa J. Determinants of the severity of exercise-induced bronchoconstriction in patients with asthma. J Asthma 2004; 41: 271-278.
19. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorti-costerone, compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181-197.
20. McFadden ER Jr. A century of asthma. Am J Respir Crit Care Med 2004; 170: 215-221.
21. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-596.
22. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24: 488-522.
23. Adcock IM, Ito K, Barnes PJ. Glucocorticoid: effects on gene transcription. Proc Am Thorac Soc 2004; 1: 247-254.
24. Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, Vignola AM. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 184-190.
25. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nature Rev Mol Cell Biol 2003; 4: 46-56.
26. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004; 3: 27-41.
27. Watson CS, Gametchu B. Proteins of multiple classes may participate in nongenomic steroid actions. Exp Biol Med 2003; 228: 1272-1281.
28. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and upregulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004; 18: 70-80.
29. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161: 918-921.
30. Paredi P, Kharitonov SA, Barnes PJ. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res 2005; 6: 15.
31. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62.
32. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998; 93: 487-490.
33. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-344.
34. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001; 20: 7168-7173.
35. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-232.
36. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
37. Nguyen C, Teo JL, Matsuda A, et al. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci USA 2003; 100: 1169-1173.
38. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3: 831-844.
39. Wilusz CJ, Wilusz J. Bringing the role of mRNA decay in the control of gene expression into focus. Trends Genet 2004; 20: 491-497.
40. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4: 372-377.
41. Clark AR, Lasa M. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr Opin Pharmacol 2003; 3: 404-411.
42. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004; 1: 255-263.
43. Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 965-1016.
44. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003; 21: 989-993.
45. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110: 603-606.
46. Thio BJ, Slingerland GL, Nagelkerke AF, Roord JJ, Mulder PG, Dankert-Roelse JE. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. Pediatr Pulmonol 2001; 32: 115-121.
47. Tillmann HC, Stuck BA, Feuring M, et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest 2004; 34: 67-73.
48. Jeffery J, Garcia J, Avner BP. Corticosteroid potentiation of catecholamine bronchodilator drugs: possible mechanisms of action. Proc West Pharmacol Soc 1979; 22: 149-153.
49. Jeffery JL, Avner BP. Blockade of uptake2: the mechanism of rapid corticosteroid induced potentiation of bronchodilator drugs in tracheal smooth muscle. Proc West Pharmacol Soc 1980; 23: 355-359.
50. Cazzola M, Santus P, Di Marco F, et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004; 17: 121-125.
51. Rodrigo G, Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: an evidence-based evaluation. Chest 1999; 116: 285-295.
52. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma (update of Cochrane Database Syst Rev 2001; CD002308; PMID: 11279763). Cochrane Database of Systematic Reviews 2003; CD002308.
53. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125: 1081-1102.
54. Suyemitsu T, Terayama H. Specific binding sites for natural glucocorticoids in plasma membranes of rat liver. Endocrinology 1975; 96: 1499-1508.
55. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991; 252: 1848-1851.
56. Gametchu B, Chen F, Sackey F, Powell C, Watson CS. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids 1999; 64: 107-119.
57. Gametchu B, Watson CS, Wu S. Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. FASEB J 1993; 7: 1283-1292.
58. Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L829-L837.
59. Horvath G, Wanner A. Molecular targets for steroids in airway vascular smooth muscle. Arch Physiol Biochem 2003; 111: 341-344.
60. Horvath G, Lieb T, Conner GE, Salathe M, Wanner A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol 2001; 25: 500-506.
61. Makara GB, Haller J. Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications. Prog Neurobiol 2001; 65: 367-390.
62. Evans SJ, Murray TF, Moore FL. Partial purification and biochemical characterization of a membrane glucocorticoid receptor from an amphibian brain. J Steroid Biochem Mol Biol 2000; 72: 209-221.
63. Borski RJ. Nongenomic membrane actions of glucocorticoids in vertebrates. Trends Endocrinol Metab 2000; 11: 427-436.
64. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002; 138: RE9.
65. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002; 67: 529-534.
66. Tumlin JA, Lea JP, Swanson CE, Smith CL, Edge SS, Someren JS. Aldosterone and dexamethasone stimulate calcineurin activity through a transcription-independent mechanism involving steroid receptor-associated heat shock proteins. J Clin Invest 1997; 99: 1217-1223.
67. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000; 130: 289-298.
68. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 473-479.
69. Whiting KP, Restall CJ, Brain PF. Steroid hormone-induced effects on membrane fluidity and their potential roles in non-genomic mechanisms. Life Sci 2000; 67: 743-757.
70. Buttgereit F. Mechanisms and clinical relevance of nongenomic glucocorticoid actions. Z Rheumatol 2000; 59: Suppl. 2, 119-123.
71. Russell JA, Kircher KW. Metabolism of norepinephrine during nerve stimulation in dog trachea. J Appl Physiol 1985; 59: 1236-1241.
72. Schildkraut JJ, Mooney JJ. Toward a rapidly acting antidepressant: the normetanephrine and extraneuronal monoamine transporter (uptake 2) hypothesis. Am J Psychiatry 2004; 161: 909-911.
73. Widdicombe JG, Webber SE. Neuroregulation and pharmacology of the tracheobronchial circulation. In: Butler J. ed. The bronchial circulation. New York/Basel/Hong Kong, Marcel Dekker, 1992; pp. 249-289.
74. Deal EC Jr, McFadden ER Jr, Ingram RH Jr, Strauss RH, Jaeger JJ. Role of respiratory heat exchange in production of exercise-induced asthma. J Appl Physiol Resp Environ Exerc Physiol 1979; 46: 467-475.
75. Pinto JM, Assanasen P, Baroody FM, Naureckas E, Solway J, Naclerio RM. Treatment of nasal inflammation decreases the ability of subjects with asthma to condition inspired air. Am J Respir Crit Care Med 2004; 170: 863-869.
76. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330: 1362-1367.
77. Cabanes L, Costes F, Weber S, et al. Improvement in exercise performance by inhalation of methoxamine in patients with impaired left ventricular function (comment). N Engl J Med 1992; 326: 1661-1665.
78. Csete ME, Abraham WM, Wanner A. Vasomotion influences airflow in peripheral airways. Am Rev Respir Dis 1990; 141: 1409-1413.
79. Blosser S, Mitzner W, Wagner EM. Effects of increased bronchial blood flow on airway morphometry, resistance, and reactivity. J Appl Physiol 1994; 76: 1624-1629.
80. James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989; 139: 242-246.
81. Gallagher SJ, Shank JA, Bochner BS, Wagner EM. Methods to track leukocyte and erythrocyte transit through the bronchial vasculature in sheep. J Immunol Methods 2002; 271: 89-97.
82. Lim LH, Bochner BS, Wagner EM. Leukocyte recruitment in the airways: an intravital microscopic study of rat tracheal microcirculation. Am J Physiol Lung Cell Mol Physiol 2002; 282: L959-L967.
83. Kelly L, Kolbe J, Mitzner W, Spannhake EW, Bromberger-Barnea B, Menkes H. Bronchial blood flow affects recovery from constriction in dog lung periphery. J Appl Physiol 1986; 60: 1954-1959.
84. Csete ME, Chediak AD, Abraham WM, Wanner A. Airway blood flow modifies allergic airway smooth muscle contraction. Am Rev Respir Dis 1991; 144: 59-63.
85. Wagner EM, Foster WM. Interdependence of bronchial circulation and clearance of 99mTc-DTPA from the airway surface. J Appl Physiol 2001; 90: 1275-1281.
86. Wanner A. Circulation of the airway mucosa. J Appl Physiol 1989; 67: 917-925.
87. Wanner A. Clinical perspectives: role of the airway circulation in drug therapy. J Aerosol Med 1996; 9: 19-23.
88. Long WM, Yerger LD, Martinez H, et al. Modification of bronchial blood flow during allergic airway responses. J Appl Physiol 1988; 65: 272-282.
89. Long WM, Yerger LD, Abraham WM, Lobel C. Late-phase bronchial vascular responses in allergic sheep. J Appl Physiol 1990; 69: 584-590.
90. Wanner A, Chediak AD, Csete ME. Airway mucosal blood flow: response to autonomic and inflammatory stimuli. Eur Respir J 1990; 3: Suppl. 12, 618s-623s.
91. Onorato DJ, Demirozu MC, Breitenbucher A, Atkins ND, Chediak AD, Wanner A. Airway mucosal blood flow in humans. Response to adrenergic agonists. Am J Respir Crit Care Med 1994; 149: 1132-1137.
92. Scuri M, McCaskill V, Chediak AD, Abraham WM, Wanner A. Measurement of airway mucosal blood flow with dimethylether: validation with microspheres. J Appl Physiol 1995; 79: 1386-1390.
93. Brieva JL, Danta I, Wanner A. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med 2000; 161: 293-296.
94. Brieva J, Wanner A. Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects. J Appl Physiol 2001; 90: 665-669.
95. Joos GF, Germonpre PR, Pauwels RA. Role of tachykinins in asthma. Allergy 2000; 55: 321-337.
96. Sylvin H, Weitzberg E, Alving K. Endothelin-induced vascular and bronchial effects in pig airways: role in acute allergic responses. J Appl Physiol 2002; 93: 1608-1615.
97. Wagner EM. TNF-alpha induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol 2000; 279: H946-H951.
98. Barker JA, Chediak AD, Baier HJ, Wanner A. Tracheal mucosal blood flow responses to autonomic agonists. J Appl Physiol 1988; 65: 829-834.
99. Zschauer AO, Sielczak MW, Wanner A. Altered contractile sensitivity of isolated bronchial artery to phenylephrine in ovalbumin-sensitized rabbits. J Appl Physiol 1999; 86: 1721-1727.
100. Carvalho P, Thompson WH, Charan NB. Comparative effects of alpha-receptor stimulation and nitrergic inhibition on bronchovascular tone. J Appl Physiol 2000; 88: 1685-1689.
101. Henderson WR, Shelhamer JH, Reingold DB, Smith LJ, Evans R 3rd, Kaliner M. Alpha-adrenergic hyper-responsiveness in asthma. N Engl J Med 1979; 300: 642-647.
102. Barnes PJ, Dollery CT, MacDermot J. Increased pulmonary alpha-adrenergic and reduced beta-adrenergic receptors in experimental asthma. Nature 1980; 285: 569-571.
103. Horvath G, Torbati A, Conner GE, Salathe M, Wanner A. Systemic ovalbumin sensitization downregulates norepinephrine uptake by rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol 2002; 27: 746-751.
104. Charan NB, Johnson SR, Lakshminarayan S, Thompson WH, Carvalho P. Nitric oxide and beta-adrenergic agonist-induced bronchial arterial vasodilation. J Appl Physiol 1997; 82: 686-692.
105. Carvalho P, Johnson SR, Charan NB. Non-cAMP-mediated bronchial arterial vasodilation in response to inhaled beta-agonists. J Appl Physiol 1998; 84: 215-221.
106. Pereira A, Mendes E, Ferreira T, Wanner A. Effect of inhaled racemic and (R)-albuterol on airway vascular smooth muscle tone in healthy and asthmatic subjects. Lung 2003; 181: 201-211.
107. Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991; 144: 51-58.
108. Svensson C, Gronneberg R, Andersson M, et al. Allergen challenge-induced entry of alpha 2-macroglobulin and tryptase into human nasal and bronchial airways. J Allergy Clin Immunol 1995; 96: 239-246.
109. Greiff L, Andersson M, Erjefalt JS, Persson CG, Wollmer P. Airway microvascular extravasation and luminal entry of plasma. Clin Physiol Func Imaging 2003; 23: 301-306.
110. McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol 1994; 266: L61-L83.
111. Baluk P, Bolton P, Hirata A, Thurston G, McDonald DM. Endothelial gaps and adherent leukocytes in allergen-induced early- and late-phase plasma leakage in rat airways. Am J Pathol 1998; 152: 1463-1476.
112. McDonald DM, Thurston G, Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999; 6: 7-22.
113. Goldie RG, Pedersen KE. Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Clin Exp Pharmacol Physiol 1995; 22: 387-396.
114. Persson CG, Erjefalt JS, Greiff L, et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998; 11: 958-970.
115. Greiff L, Wollmer P, Andersson M, Svensson C, Persson CG. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax 1998; 53: 1010-1013.
116. Greiff L, Erjefalt I, Erjefalt JS, Wollmer P, Sundler F, Persson CG. Effects of topical platelet activating factor on the guinea-pig tracheobronchial mucosa in vivo. Acta Physiol Scand 1997; 160: 387-391.
117. Erjefalt I, Persson CG. Pharmacologic control of plasma exudation into tracheobronchial airways. Am Rev Respir Dis 1991; 143: 1008-1014.
118. Damazo AS, Tavares de Lima W, Perretti M, Oliani SM. Pharmacological modulation of allergic inflammation in the rat airways and association with mast cell heterogeneity. Eur J Pharmacol 2001; 426: 123-130.
119. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
120. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003; 33: 595-599.
121. Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax 2002; 57: 885-888.
122. Rogers DF, Belvisi MG, Aursudkij B, Evans TW, Barnes PJ. Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs. Br J Pharmacol 1988; 95: 1109-1116.
123. McDonald DM, Bowden JJ, Baluk P, Bunnett NW. Neurogenic inflammation. A model for studying efferent actions of sensory nerves. Adv Exp Med Biol 1996; 410: 453-462.
124. Halldorsdottir H, Greiff L, Wollmer P, et al. Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha 2-macroglobulin. Thorax 1997; 52: 964-968.
125. Erjefalt I, Persson CG. Effects of adrenaline and terbutaline on mediator-increased vascular permeability in the cat trachea. Br J Pharmacol 1982; 77: 399.
126. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
127. Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004; 4: 711-724.
128. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003; 24: 640-647.
129. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
130. Wagner JG, Roth RA. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 2000; 52: 349-374.
131. Virchow R. Gesammelte Werke. In: Abhandlungen zur Wissenschlaftlichen Medizin. Frankfurt, Meidinger 1856; pp. 285-286.
132. Cudkowicz L. Leonardo da Vinci and the bronchial circulation. Br J Dis Chest 1953; 47: 23-30.
133. Guillot N. Recherches anatomiques et pathologiques sur les amas de charbon products pendant la vie dans les organes respiratories de l'homme. Arch Gen Med 1845; 7: 151-284.
134. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
135. Wilson J. The bronchial microcirculation in asthma. Clin Exp Allergy 2000; 30: Suppl. 1, 51-53.
136. Woods DA, Miller M. The role of the dual pulmonary circulation in various pathologic conditions of the lung. J Thorac Surg 1938; 7: 649-670.
137. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13: 27-33.
138. Carroll NG, Cooke C, James AL. Bronchial blood vessel dimensions in asthma. Am J Respir Crit Care Med 1997; 155: 689-695.
139. Hoshino M, Takahashi M, Takai Y, Sim J, Aoike N. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 2001; 31: 722-730.
140. Hoshino M, Aoike N, Takahashi M, Nakamura Y, Nakagawa T. Increased immunoreactivity of stromal cell-derived factor-1 and angiogenesis in asthma. Eur Respir J 2003; 21: 804-809.
141. Tanaka H, Yamada G, Saikai T, et al. Increased airway vascularity in newly diagnosed asthma using a high-magnification bronchovideoscope. Am J Respir Crit Care Med 2003; 168: 1495-1499.
142. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
143. Baluk P, Lee CG, Link H, et al. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol 2004; 165: 1071-1085.
144. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-1103.
145. Dahlqvist A, Umemoto EY, Brokaw JJ, Dupuis M, McDonald DM. Tissue macrophages associated with angiogenesis in chronic airway inflammation in rats. Am J Respir Cell Mol Biol 1999; 20: 237-247.
146. Baluk P, Raymond WW, Ator E, Coussens LM, McDonald DM, Caughey GH. Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol 2004; 287: L307-L317.
147. Redington AE, Roche WR, Madden J, et al. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J Allergy Clin Immunol 2001; 107: 384-387.
148. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86: 608-610.
149. Shishido H, Kikuchi S, Heckman H, Myers RR. Dexamethasone decreases blood flow in normal nerves and dorsal root ganglia. Spine 2002; 27: 581-586.
150. Ginsburg J. Influence of intra-arterial hydrocortisone on adrenergic responses in the hand. BMJ 1958; 424-427.
151. Kalsner S. Sensitization of noradrenaline responses by inhibitors of extraneuronal uptake in a coronary artery preparation. Br J Pharmacol 1974; 51: 453-455.
152. Ohkubo H, Chiba S. Vascular responses of ophthalmic arteries to exogenous and endogenous norepinephrine. Exp Eye Res 1989; 48: 539-547.
153. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thor Soc 2004; 1: 235-238.
154. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46: 589-597.
155. Fritz I, Levine R. Action of adrenal cortical steroids and norepinephrine on vascular responses of stress in adrenalectomized rats. Am J Physiol 1951; 165: 456-465.
156. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001; 91: 35-62.
157. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004; 43: 169-175.
158. Iversen LL, Salt PJ. Inhibition of catecholamine uptake-2 by steroids in the isolated rat heart. Br J Pharmacol 1970; 40: 528-530.
159. Chan CC, Kalsner S. Termination of responses to sympathetic nerve stimulation and to noradrenaline in a perfused arterial preparation: the role of neuronal and extraneuronal uptake. J Pharmacol Exp Ther 1982; 222: 731-740.
160. Kalsner S. Role of extraneuronal mechanisms in the termination of contractile responses to amines in vascular tissue. Br J Pharmacol 1975; 53: 267-277.
161. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 2004; 25: 375-381.
162. Steiner A, Locher R, Sachinidis A, Vetter W. Cortisol-stimulated phosphoinositide metabolism in vascular smooth muscle cells: a role for glucocorticoids in blood pressure control? J Hypertens Suppl. 6, 1989; 7: S140-S141.
163. + exchange activity in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int 2000; 57: 2319-2333.
164. 2+ in vascular smooth-muscle cells. Circ Res 1995; 76: 973-979.
165. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci 2002; 966: 108-118.
166. Goulding NJ. The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Curr Opin Pharmacol 2004; 4: 629-636.
167. Hinz B, Hirschelmann R. Dexamethasone megadoses stabilize rat liver lysosomal membranes by non-genomic and genomic effects. Pharm Res 2000; 17: 1489-1493.
168. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 2002; 135: 511-519.
169. Schmid D, Burmester GR, Tripmacher R, Kuhnke A, Buttgereit F. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000; 20: 289-302.
170. Baccan GC, Oliveira RDR, Mantovani B. Stress and immunological phagocytosis: possible nongenomic action of corticosterone. Life Sci 2004; 75: 1357-1368.
171. Long F, Wang YX, Liu L, Zhou J, Cui RY, Jiang CL. Rapid nongenomic inhibitory effects of glucocorticoids on phagocytosis and superoxide anion production by macrophages. Steroids 2005; 70: 55-61.
172. Liu L, Wang YX, Zhou J, et al. Rapid non-genomic inhibitory effects of glucocorticoids on human neutrophil degranulation. Inflamm Res 2005; 54: 37-41.
173. Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 1999; 41: 55-64.
174. Perretti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation 2000; 7: 147-161.
175. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004; 2: 1-12.
176. Busse W, Banks-Schlegel S, Noel P, et al. Future research directions in asthma: an NHLBI Working Group report. Am J Respir Crit Care Med 2004; 170: 683-690.
177. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-389.
178. Smith L, Smith JB. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. J Biol Chem 1994; 269: 27527-27531.
179. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994; 23: 25-30.
180. Brem AS, Bina RB, Mehta S, Marshall J. Glucocorticoids inhibit the expression of calcium-dependent potassium channels in vascular smooth muscle. Mol Genet Metab 1999; 67: 53-57.
181. Murasawa S, Matsubara H, Kizima K, Maruyama K, Mori Y, Inada M. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension 1995; 26: 665-669.
182. Nuglozeh E, Mbikay M, Stewart DJ, Legault L. Rat natriuretic peptide receptor genes are regulated by glucocorticoids in vitro. Life Sci 1997; 61: 2143-2155.
183. Fishel RS, Eisenberg S, Shai SY, Redden RA, Bernstein KE, Berk BC. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension 1995; 25: 343-349.
184. Provencher PH, Villeneuve A, Morin C. Glucocorticoids increase preproendothelin-1 expression in rat aorta. Endocr Res 1998; 24: 737-741.
185. Muto S, Nemoto J, Ebata S, Kawakami K, Asano Y. Corticosterone and 11-dehydrocorticosterone stimulate Na,K-ATPase gene expression in vascular smooth muscle cells. Kidney Int 1998; 54: 492-508.
186. Mendelsohn FA, Lloyd CJ, Kachel C, Funder JW. Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo. J Clin Invest 1982; 70: 684-692.
187. Wallerath T, Witte K, Schafer SC, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 1999; 96: 13357-13362.
188. Schafer SC, Wallerath T, Closs EI, et al. Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles. Am J Physiol Heart Circ Physiol 2005; 288: H436-H444.
189. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986; 119: 62-69.
190. Inoue H, Umesono K, Nishimori T, Hirata Y, Tanabe T. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem Biophys Res Commun 1999; 254: 292-298.
191. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92: 81-87.
192. Kalavantavanich K, Schramm CM. Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1101-L1106.
193. Kornel L, Prancan AV, Kanamarlapudi N, Hynes J, Kuzianik E. Study on the mechanisms of glucocorticoid-induced hypertension - glucocorticoids increase transmembrane Ca2+ influx in vascular smooth-muscle in-vivo. Endocr Res 1995; 21: 203-210.
194. Xiao D, Huang X, Bae S, Ducsay CA, Zhang L. Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy. Am J Physiol Heart Circ Physiol 2002; 283: H238-H246.
195. Piedimonte G, McDonald DM, Nadel JA. Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea. J Clin Invest 1990; 86: 1409-1415.
196. Schoonbrood DFM, Out TA, Lutter R, Reimert CM, Vanoverveld FJ, Jansen HM. Plasma-protein leakage and local secretion of proteins assessed in sputum in asthma and COPD - the effect of inhaled corticosteroids. Clin Chim Acta 1995; 240: 163-178.
197. Vandegraaf EA, Out TA, Roos CM, Jansen HM. Respiratory membrane-permeability and bronchial hyperreactivity in patients with stable asthma - effects of therapy with inhaled steroids. Am Rev Respir Dis 1991; 143: 362-368.
198. Piedimonte G, McDonald DM, Nadel JA. Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea. J Clin Invest 1991; 88: 40-44.
199. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids - the glucocorticoid receptor regulates leukocyte adhesion to endothelial-cells and expression of endothelial leukocyte adhesion molecule-1 and intercellular-adhesion molecule-1. Proc Natl Acad Sci USA 1992; 89: 9991-9995.
200. Cengizlier R, Demirpolat E, Tulek N, Cakmak F. Circulating ICAM-1 levels in bronchial asthma and the effect of inhaled corticosteroids. Ann Allergy Asthma Immunol 2000; 84: 539-541.
201. Pipitone N, Sinha M, Theodoridis E, et al. The glucocorticoid inhibition of LFA-1 and CD2 expression by human mononuclear cells is reversed by IL-2, IL-7 and IL-15. Eur J Immunol 2001; 31: 2135-2142.
202. Hakonarson H, Halapi E, Whelan R, Gulcher J, Stefansson K, Grunstein MM. Association between IL-1beta/TNF-alpha-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am J Respir Cell Mol Biol 2001; 25: 761-771.
203. Lange P, Parner J, Vestbo J, Schnohr P, Jensen GA. 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-1200.
204. Boulet LP, Laviolette M, Turcotte H, et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest 1997; 112: 45-52.
205. Orsida BE, Ward C, Li X, et al. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164: 117-121.
206. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178: 347-355.
207. Kharitonov SA, Barnes PJ. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thor Soc 2004; 1: 191-199.
208. Noon JP, Evans CE, Haynes WG, Webb DJ, Walker BR. A comparison of techniques to assess skin blanching following the topical application of glucocorticoids. Br J Dermatol 1996; 134: 837-842.
209. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97: 169-176.
210. Wilson AM, Coutie WJ, Sims EJ, Lipworth BJ. The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. Eur J Clin Pharmacol 2003; 58: 643-647.
211. Hammond GL. Determinants of steroid hormone bioavailability. Biochem Soc Trans 1997; 25: 577-582.
212. Mariassy AT, Gazeroglu H, Wanner A. Morphometry of the subepithelial circulation in sheep airways. Effect of vascular congestion. Am Rev Respir Dis 1991; 143: 162-166.
213. Baile EM, Sotres-Vega A, Pare PD. Airway blood flow and bronchovascular congestion in sheep. Eur Respir J 1994; 7: 1300-1307.
214. Cabanes LR, Weber SN, Matran R, et al. Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function. N Engl J Med 1989; 320: 1317-1322.
215. Wagner EM, Mitzner W. Effects of bronchial vascular engorgement on airway dimensions. J Appl Physiol 1996; 81: 293-301.
216. Pellegrino R, Dellaca R, Macklem PT, et al. Effects of rapid saline infusion on lung mechanics and airway responsiveness in humans. J Appl Physiol 2003; 95: 728-734.